Tofacitinib: A Promising Future in Type II Rheumatoid Arthritis

Speciality: Rheumatology


Speaker:

Dr. Sundeep Upadhyaya | MD, DM

Dr. Sonal Mehra | DM Clinical Immunology & Rheumatology

Dr. Chanchal Gera | MD, FIACM, EULAR-C (Rheumatology), Senior Consultant (Dept of Medicine & Rheumatology)

Description:

A warm welcome to all the medical professionals in this interesting session of use of JAK inhibitor drugs tofacitinib in rheumatoid arthritis. We have Dr. Sundeep Upadhyaya, Dr. Sonal Mehra, Dr. Chanchal Gera to lead the session.

Immunological pathways play a crucial role in disease management especially in the case of rheumatological disease. Managing rheumatoid arthritis often becomes difficult due to its rate of progression and associated health issues. 

The webinar will help in gaining important insights on JAK inhibiting drugs like tofacitinib in controlling rheumatoid arthritis. It is a competitive inhibitor of JAK that binds to adenosine triphosphate in the kinase domain.

Tofacitinib inhibits the process of intracellular signaling from the receptor to the cellular nucleus and inhibits the inflammation process via inhibition of the Janus kinases, which eventually helps in controlling rheumatoid arthritis.

Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study opens up possibility of bespoke prostate cancer treatment

2.

Why Encouragement May Not Improve Motivation in Depression

3.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot